Shares of Accretion Pharmaceuticals Limited skyrocketed 17.3% on the NSE, following the company’s stellar financial performance in H2 FY25. The pharmaceutical firm, known for its tablets, capsules, and healthcare products, reported a net profit surge of 187% year-on-year, fueling investor optimism.
🔴 Key Highlights:
- Revenue from operations hit ₹38.8 crore, marking a 109% half-on-half (HoH) growth from ₹18.6 crore in H1 FY25.
- Net profit soared to ₹4.3 crore, reflecting a 72% HoH increase and a 187% YoY jump from ₹1.5 crore in H2 FY24.
- EBITDA surged 188% YoY, reaching ₹7.5 crore, with an EBITDA margin expansion to 19.43%.
- Accretion Pharmaceuticals’ market capitalization now stands at ₹89 crore, with shares trading at ₹79.9, up 14.5% intraday.
📢 Market Analysts’ Take:
“The company’s strong earnings growth and expanding margins indicate robust demand for its pharmaceutical products. Investors are bullish on its future trajectory.”
⚠️ Strategic Impact:
- The stock’s rally underscores investor confidence, as Accretion Pharmaceuticals continues to scale its manufacturing and distribution network.
- The pharma sector remains a hotbed for growth, with companies focusing on innovation and global expansion.
👉 What do you think? Will Accretion Pharmaceuticals sustain its growth momentum? Drop your thoughts in the comments!
🔴 Share this post to keep investors informed! 🚀🔥
